Home/Pipeline/FP-004 (SIF Formulation)

FP-004 (SIF Formulation)

Opioid Use Disorder

PreclinicalActive

Key Facts

Indication

Opioid Use Disorder

Phase

Preclinical

Status

Active

Company

Foresee Pharmaceuticals

About Foresee Pharmaceuticals

Foresee Pharmaceuticals is a purpose-driven, clinical-stage biopharma focused on improving patient quality of life through innovative drug delivery and novel therapeutics. Its core strategy is built on two pillars: a proprietary Stabilized Injectable Formulation (SIF) platform for creating long-acting injectables that enhance compliance, and a pipeline of first/best-in-class New Chemical Entities (NCEs) for severe, underserved diseases. Key achievements include advancing multiple programs into late-stage clinical trials, such as FP-045 for Fanconi Anemia and its SIF-based Leuprolide for Central Precocious Puberty, while establishing a global partnership strategy to commercialize its products worldwide.

View full company profile

Therapeutic Areas

Endocrinology Rare Diseases Pulmonary Fibrosis Opioid Use Disorder

Other Opioid Use Disorder Drugs

Drug	Company	Phase	Status
TRV734	Trevena	Phase 1	Active
Safer Ibogaine Analogs	Gilgamesh Pharmaceuticals	Pre-clinical/Research	Active (NIDA Grant Funded)
AM-510	Aion Medicines	Discovery	Active
Naltrexone Implant	Delpor	Phase 1	Active
Platform Expansion	Amygdala Neurosciences	Research	Active
Undisclosed OUD Program	Epiodyne	Pre-clinical	Active
AQL™-Naltrexone	Plumb Pharmaceuticals	Pre-clinical	Active
MEB-1170	Mebias Discovery	Phase 1	Active
SUBLOCADE®	Indivior PLC	Marketed	Commercial